184 POST-TRANSCRIPTIONAL REGULATION OF CYCLOOXYGENASE-2 EXPRESSION BY MICRORNA-199a* IN HUMAN OA CHONDROCYTES  by Akhtar, N. et al.
S88 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
caused an upregulation of SOX9 and enhanced extracellular matrix protein
production.
Conclusions: Depletion of PHD2 resulted in greater HIF-2α levels, and
therefore enhanced SOX9-induced cartilage matrix production compared
to the levels normally found in hypoxia (1% oxygen) implying that PHD2
inhibition offers a novel means to promote the chondrocyte phenotype and
enhance cartilage repair in vivo.
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CARTILAGE-SPECIFIC KNOCKOUT OF SITE-1 PROTEASE IN POSTNATAL
MICE RESULTS IN AN ABNORMAL GROWTH PLATE WITH DISRUPTION OF
HYPERTROPHIC CHONDROCYTE DIFFERENTIATION AND SUBSEQUENT
CHONDRODYSPLASIA
D. Patra, E. DeLassus, S. Hayashi, L.J. Sandell
Washington Univ. Sch. of Med., St. Louis, MO
Purpose: Site-1 protease (S1P) is a proprotein convertase that plays an
essential role in the processing of latent, membrane-bound transcription
factors such as SREBPs and ATF6, to their active form. Cartilage-speciﬁc
knockout of S1P in mice (S1Pcko) results in chondrodysplasia with complete
lack of endochondral bone formation. These mice exhibited poor cartilage
development with a drastic decrease of collagen type IIB (Col IIB) in the
matrix. Most of the Col IIB appears trapped inside the cell. Ultrastructural
analysis of the cartilage showed engorged and fragmented endoplasmic
reticulum. S1Pcko mice die during or very soon after birth and therefore the
study was restricted to embryonic time-points. The goal of this study is to
investigate the role of S1P in cartilage/endochondral bone development at
various developmental stages in postnatal mice with the intent to identify
and dissect S1P-regulated pathways fundamental to skeletal development.
Methods: S1Pf/f mice (homozygous for the S1Pﬂox allele with ﬂoxed S1P
exon 2) were crossed with Col2-CreER(T) mice (positive for Col2-CreER(T)
transgene where Cre recombinase-mutant estrogen receptor [ER(T)] fusion
protein is active only in presence of tamoxifen) and the progeny back-
crossed with S1Pf/f to create S1Pf/f;Col2-CreER(T) mice. Cartilage-speciﬁc
deletion of S1P in postnatal mice (S1Pcko-ER(T)) was achieved by injecting
S1Pf/f;Col2-CreER(T) mice with tamoxifen at P1 (1 day old) or P7 (7 day
old) timepoints and harvested a week or more later. Tamoxifen injections
were done for some pregnant mice at E18.5. The cartilage/bone from
S1Pcko-ER(T) mice and its wild type (WT) littermates were studied by X-
ray microtomograph (Micro-CT), histology, immunohistochemistry (IHC),
immunoﬂuorescence (IF), and in situ hybridization.
Results: S1Pcko-ER(T) mice exhibit chondrodysplasia with severity depending
on the timing of tamoxifen injection after birth. The younger the injected
animals, the more pronounced the difference from its WT littermates, with
tamoxifen injection of the mother at E18.5 being the most drastic. Micro-
CT analysis of femurs and humeri showed that the bones in S1Pcko-ER(T)
mice were smaller with abnormal trabecular development. S1Pcko-ER(T) mice
appeared osteoporotic with drastically reduced trabecular bone (Fig. 1).
Trabecular bone developed in an arbitrary fashion with individual trabecu-
lae being thicker, with higher bone mineral density and with more spacing
between them, than in WT. Histological analysis showed that chondrocyte
hypertrophic differentiation was disrupted in S1Pcko-ER(T) mice and further
conﬁrmed by a loss of type X collagen expressing cells in the growth plate.
S1Pcko-ER(T) mice injected at P1 did not develop a secondary ossiﬁcation
center; IHC and IF analysis of these mice demonstrated that Col IIB was
trapped primarily inside cells which would otherwise differentiate to be
hypertrophic in the secondary ossiﬁcation center in WT.
Figure 1. Micro-CT analysis of femurs from WT and S1Pcko-ER(T) mice showing the osteo-
porotic nature of the femur in the mutant mice.
Conclusions: S1P is essential to endochondral bone development in post-
natal mice. Bone lengthening is drastically reduced in S1Pcko-ER(T) mice. The
absence of type X collagen expressing cells in S1Pcko-ER(T) mice suggests
a defective growth plate diminishing bone elongation and implicates S1P
in regulating hypertrophic differentiation in postnatal mice. As this is
not seen in the S1Pcko mice, S1P may have additional roles in postnatal
mice toward skeletal development. The entrapment of Col IIB in the
hypertrophic differentiation-arrested cells underscores a role for S1P in
cartilage matrix homeostasis. The osteoporotic nature of the bone alludes
to the importance of S1P in maintaining endochondral bone homeostasis.
The phenotype in S1Pcko-ER(T) mice is similar to that seen in humans with
congenital achondroplasia and this attests to the fundamental requirement
of S1P in mammalian skeletal development. Understanding this fundamen-
tal requirement should be useful in treating cartilage diseases and tissue
engineering.
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POST-TRANSCRIPTIONAL REGULATION OF CYCLOOXYGENASE-2
EXPRESSION BY MICRORNA-199a* IN HUMAN OA CHONDROCYTES
N. Akhtar, Z. Rasheed, T.M. Haqqi
MetroHlth. Med. Ctr./CWRU, Cleveland, OH
Purpose: MicroRNAs (miRNAs) are small non-coding RNAs that modify
the properties of the cells by altering the translational proﬁle of mRNAs
to produce a proteome with unique functional properties. Interleukin-1β
(IL-1β) mediated over expression of cyclooxygenase-2 (COX-2) contributes
to the inﬂammation and joint degeneration in osteoarthritis (OA) patients.
In this study we determined the posttranscriptional regulation of COX-2 by
miRNAs in human OA and normal chondrocytes stimulated with IL-1β.
Methods: Chondrocytes were derived by enzymatic digestion following
our standard protocol using cartilage from normal (trauma cases with
no history of OA) and OA patients undergoing total joint arthroplasty.
Isolated chondrocytes were stimulated with IL-1β (5 ng/ml) in vitro. Total
RNA was prepared using the TRIZOL reagent and miRNAs were puriﬁed
using the mirVANA system. Single stranded cDNA was synthesized using
stem loop-speciﬁc primers and the expression of miRNAs of interest was
quantiﬁed using TaqMan miRNA expression assay and their target mRNA
was identiﬁed using bioinformatics. Transfection of chondrocytes with a
3’UTR reporter construct and pre-miRNAs was employed to verify the
miRNA:mRNA interaction. Expression of COX-2 mRNA was determined by
qRT-PCR using validated primers. Expression of COX-2 protein in OA chon-
drocytes transfected with pre-miRNAs and anti-miRNAs was determined by
Western immunoblotting. Role of p38-MAPKs and NF-κB in the regulation
of miRNAs and COX-2 expression in chondrocytes was evaluated using
speciﬁc inhibitors. Data was analyzed using Origin 6.1 software package
and p<0.05 was considered signiﬁcant.
Results: We recently performed the miRNAs expression proﬁle in human
OA chondrocytes stimulated with IL-1β and discovered that the expression
of several miRNAs, including miR-101_3, and miR-199a*, was suppressed
signiﬁcantly (>2 fold, p<0.05). Kinetic analysis showed a differential pat-
tern of expression of miR-101_3, and miR-199a* miRNAs at 6 and 24
h post-stimulation with IL-1β. In human OA chondrocytes, expression
of miR-101_3 was down regulated at 6 h (2.1-fold ± 1.0; n=7) but no
signiﬁcant change was observed at 24 h (n=11). In contrast, normal human
chondrocytes showed down regulation of miR-101_3 (1.7-fold ± 0.53; n=3)
at 24 h with no change at 6 h post-stimulation with IL-1β. Expression of
miR-199a* was signiﬁcantly down regulated in OA chondrocytes stimulated
with IL-1β at 24 h (3.3-fold ± 1.5; n=11, p<0.05) but not at 6 h (0.94-fold
± 0.86; n=7, p>0.05). Importantly, in human OA chondrocytes stimulated
with IL-1β expression of COX-2 protein was also found to be high at 24 h,
compared to 6 h post stimulation and this inversely correlated with the
expression of miR-199a*. Normal human chondrocytes also showed similar
inverse correlation of COX-2 protein and miR-199a* expression at 6 h
(1.1-fold ±0.023; n=3, p>0.05) and 24 h (2.2-fold ± 0.65; n=3, p<0.05) after
stimulation with IL-1β. In silico analysis identiﬁed the sequences conserved
in the 3’UTR of human COX-2 mRNA (NM_000963) complimentary to the
seed sequence of miR-101_3, and miR-199a*. Over expression of miR-199a*
in human OA chondrocytes inhibited the IL-1β-induced expression of COX-
2 protein. On the other hand transfection with an inhibitor of miR-199a*
enhanced the IL-1β-induced expression of COX-2 protein in human OA
chondrocytes. Co-transfection of human OA chondrocytes with a luciferase
reporter construct containing the 3’-UTR of human COX-2 mRNA and the
miR-199a* mimic suppressed the luciferase enzyme activity signiﬁcantly
(p<0.001). No inhibition of luciferase enzyme activity was observed in
OA chondrocytes transfected with either miR-199a* inhibitor or scrambled
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miRNA sequences. Inhibition of NF-κB and p38-MAPK activation with spe-
ciﬁc inhibitors down-regulated the expression of COX-2 but up-regulated
the expression of miR-101_3, miR-199a* in human OA chondrocytes sug-
gesting negative regulation of miR-101_3, miR-199a* by the activation of
these pathways.
Conclusions: Our data implicate miR-199a* in the post transcriptional
regulation of COX-2 expression in human OA chondrocytes. These results
also identify miR-199a* as a novel therapeutic target for the treatment of
OA.
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ROLE OF C-TYPE NATRIURETIC PEPTIDE (CNP) IN OSTEOGENESIS AND
TREATMENT OF OSTEOPOROSIS
H. Bukulmez1,2 , T. Haqqi2, F. Khan1, J.F. Welter1, S. Murakami1
1Case Western Reserve Univ., Cleveland, OH; 2MetroHlth.Med. Ctr., Cleveland,
OH
Purpose: The recently described C-type natriuretic peptide (CNP) is critical
for normal longitudinal growth in humans and plays a central role in
osteoblast regulation in bone formation and regeneration. The purpose of
this study was to determine whether CNP has therapeutic potential in
osteoporosis or osteopenia secondary to inﬂammatory arthritis. Our goal
was to test whether CNP overproduction can reverse the osteoporosis that
develops in mouse disease models due to a lack of proper numbers and
function of osteoblasts to balance the resorptive effect of osteoclasts.
Methods: CNPCOL2A1TG mice have been generated by cloning human CNP
cDNA into a construct that contained the mouse collagen type II (COL2A1)
promoter and enhancer (GenBank #m65161). We initially assessed the
bone phenotype of mice that over-express CNP in chondrocytes in vivo.
We then made primary chondrocyte and osteoblast cultures from mouse
rib cage cartilage and calvarial osteoblasts. RNA and protein collected were
used to measure osteoblastic activity. We induced osteoporosis/osteopenia
by inducing chronic inﬂammatory arthritis in mice that over expressed CNP
compared to wild type in vivo.
Results: Phenotypic characteristics of the CNP over-expressing mice be-
came evident at 3-4 weeks of age. There was excessive elongation and
noticeable widening of the distal ends of long bones. Increased bone tra-
beculation in both primary and secondary ossiﬁcation centers was obvious
in histology, at 8-9 weeks of age in CNPCOL2A1TG mice. Micro-CT analysis
of age- and sex-matched littermates (4 female, 7 male), both wild type
and CNPCOL2A1TG, at various ages were analyzed. CNPCOL2A1TG mice showed
higher bone mineral density (BMD) and content (BMC) in the subchondral
bone in proximal tibia (Table 1). Trabeculation in the subchondral bone and
under the growth plate in CNPCOL2A1TG mice was also increased. CNPCOL2A1TG
mouse serum showed signiﬁcantly higher osteocalcin levels compared to
wild type from 8-13 weeks (p<0.005).
Table 1. Spine m-CT
Avg TbTh (μm) Trabecular BMC (mg) Cortical BMC (mg)
8 wk f WT (n=2) 50.57 (±1.02) 4.80 (±0.18) 7.65 (±0.2)
8 wk f CNPCOL2A1TG (n=2) 52.44 (±0.12) 6.95 (±0.03) 9.90 (±0.8)
14 wk f WT (n=4) 77.70 (±1.2) 3.51 (± 0.80) 8.16 (±0.9)
14 wk f CNPCOL2A1TG (n=2) 91.40 (±2.4) 7.43 (±1.20) 13.57 (±1.3)
Quantitative RT-PCR analysis showed that, in both primary chondrocytes
and osteoblast cultures, collagen II, X, I, OPG, osteocalcin were expressed
at signiﬁcantly higher levels in the CNPCOL2A1TG mouse chondrocytes or
when calvarial osteoblasts were treated with exogenous CNP (10ng/ml,
> 3wk). However, RANKL mRNA was found to be decreased 2.5 fold
in CNPCOL2A1TG mouse chondrocytes and osteoblasts. When we induced
systemic arthritis using the K/BxN TCR serum model in mice (n=32) that
were either CNPCOL2A1TG or wild type, the CNPCOL2A1TG mice did not develop
Figure 1. Osteocalcin (ng/ml).
endochondral delay or periarticular bone loss/osteoporosis even after 4
weeks of systemic arthritis compared to wild type. Serum osteocalcin lev-
els, measured after the K/BxN TCR arthritis developed, showed decreased
levels at 2.5, 3.5 and 5 months-of-age (Fig. 1). Interestingly, CNPCOL2A1TG
mice continued to maintain high osteocalcin levels even after arthritis
developed. Micro-CT analysis suggested that CNPCOL2A1TG mice that devel-
oped arthritis were resistant to both trabecular and cortical bone mineral
density loss due to inﬂammatory changes in the joint. Trabecular thickness,
inter-trabecular space and the connectivity of the trabecular structure were
not different in wild type (WT) and K/BxN TCR mice.
Conclusions: Our observations from in vivo and in vitro experiments sug-
gest a clear effect of CNP signaling in osteogenesis and suggest a role in
osteoporosis treatment during systemic arthritis.
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THE ROLE OF FIBROBLAST GROWTH FACTOR 2 (FGF2) IN THE CELLULAR
RESPONSE TO INJURY FOLLOWINGMURINE CARTILAGE EXPLANTATION
K. Chong, J. Skalatvla, T.L. Vincent
Kennedy Inst. of Rheumatology, London, United Kingdom
Purpose: Studies from our lab have previously demonstrated that there
is rapid activation of a number of intracellular signalling pathways upon
explantation of porcine articular cartilage including the three mitogen acti-
vated protein kinases (MAPKs); c-jun N terminal kinase (JNK), p38, and the
extracellularly regulated kinase (ERK) (Gruber, 2004), as well as activation
of NFkB and PI3 kinase (unpublished). Re-cutting cartilage that has been
rested in serum free medium for 48h results in activation of the ERK
pathway only, and is due to release of FGF2 from the pericellular matrix.
In order to determine the relative contribution of FGF2 to the explantation
response, we set up signalling assays and studied gene induction in injured
murine hip cartilage from wild type (WT) and FGF2 null mice.
Methods: Murine cartilage from 4-6 week old WT or FGF2 null mice was
explanted from the intact hip by blunt dissection, and was either lysed
immediately, or was cultured in serum free medium for up to 24h. Some
explanted cartilage was rested in serum free medium (48h), then was
re-cut. Protein was extracted from the hips (3-5 for signalling experiments)
for phospho-western blotting for pERK, pJNK, pP38 and pIkappaB. Equal
protein loading was conﬁrmed by re-blotting for total ERK, IkB or tubulin.
Gene analysis was performed on 5-8 hip explants (either explanted, re-cut
or stimulated with FGF2). Messenger RNA was extracted using Trizol and
puriﬁed. Quantitative RT-PCR for 48 pre-selected candidate genes using
Taqman microﬂuidic cards was performed.
Results: Cartilage explantation led to early activation of MAPK pathways as
well as causing phosphorylation of IkB, indicative of activation of NFkB. A
very weak activation of inﬂammatory pathways was apparent when rested
cartilage was re-cut. When FGF2 null cartilage was explanted there was
an approximate 50% reduction in MAPK activation. A number of genes (se-
lected from an unpublished murine OA microarray study) were regulated
in the chondrocytes following explantation. These are listed in Table 1.
Some of these genes were also regulated when the tissue was re-cut (rather
than explanted), and those same genes were shown to be strongly induced
by stimulation with recombinant FGF2. CCL2, arginase 1, IL-1α, CCL7 and
Table 1
Legend: Arg1 - arginase 1; CCL - CC chemokine ligand; HAS1 - hyaluronan synthase 1;
CD14 - cluster differentiation 14; TNFRSF12a - TNF Receptor superfamily member 12a;
TSG6 - TNF stimulated gene 6; TIMP1 - tissue inhibitor of metalloproteinase 1; Ptges -
prostaglandin E synthase.
